Antibody Drug Design
Antibody drug design is a pivotal discipline in contemporary biomedicine, particularly for the treatment of cancers, autoimmune disorders, and infectious diseases. Monoclonal antibodies have demonstrated remarkable therapeutic success across a broad spectrum of indications. Conventional antibody design relies on extensive laboratory work and animal studies, making the process both time-intensive and resource-intensive.
ICDMO provides comprehensive AI-driven antibody drug design services. Our state-of-the-art deep learning models accurately predict antibody structures, optimise binding affinity and target specificity, and forecast in vivo biological efficacy — enabling clients to develop highly effective antibody therapeutics with greater speed. Every computational stage is complemented by wet laboratory validation, ensuring thoroughness, reducing risk, and materially improving overall success rates.
We support antibody drug design through two methods:
Library Screening Based on Embedding Large Models
Our sequence library screening service integrates a broad range of cutting-edge computational architectures, including LSTM (Long Short-Term Memory networks), Transformers, BERT (Bidirectional Encoder Representations from Transformers), Variational Autoencoders (VAEs), and Generative Adversarial Networks (GANs). By applying these models for deep optimisation and self-supervised learning, we achieve substantial improvements in prediction accuracy through precise sequence generation and intelligent candidate prioritisation.
Figure 1. The overall workflow for our proposed sequence generation and prioritisation scheme is based on LSTM.
By choosing our service, you receive a fully integrated, end-to-end antibody development solution encompassing sequence design, library construction, systematic screening, and experimental validation. This all-inclusive approach dramatically increases research and development efficiency and success rates while simultaneously reducing development costs and de-risking each programme milestone.
1
Library Construction
Antibody samples are collected from specific sources such as human immune libraries or B cells, transcribed into cDNA, and inserted into expression vectors to construct a high-diversity antibody display library.
2
Screening
The antibody display library is exposed to immobilised target antigens. Through multiple rounds of panning under progressively stringent conditions, antibodies with specific binding to the target antigen are significantly enriched.
3
Selection and Characterisation
Binding-positive antibody clones are selected and subjected to sequence analysis and biophysical characterisation using SPR or ELISA to identify candidates with optimal affinity, specificity, and developability profiles.
4
Wet Lab Validation
Beyond computational sequence generation, we provide full experimental validation to confirm that selected antibodies function as intended, exhibit the required stability, and meet pre-defined performance benchmarks.
Target-Based de novo Design
Lead optimisation and de novo design are the two central pillars of our AI-driven antibody development service. By leveraging generative AI models, we enable zero-shot design of antibody CDRs for specific targets, screening large variant libraries to identify sequences with optimal binding affinity. Our models have demonstrated high effectiveness in designing all CDRs of the antibody heavy chain, as confirmed by SPR characterisation. In addition, our high-throughput screening assay — validated against SPR data — generates quantitative binding affinity scores for large panels of antibody variants. Large language models trained on this data can predict binding affinities for novel, unseen variants, directly enabling the development of antibodies with substantially improved characteristics. Our service takes a holistic approach by simultaneously co-optimising multiple properties, thereby accelerating and de-risking the entire antibody drug development process.
Figure 2. Deep learning models trained on antibody–antigen interactions, complemented by high-throughput experiments, can design antibodies that bind to antigens unseen by the models without requiring further affinity optimisation. (Shanehsazzadeh, A., et al., 2024)
1
Database Integration
Curate and consolidate relevant data from major biological and structural databases, ensuring comprehensive and high-quality input for all AI models.
2
Target Analysis
Perform in-depth analysis of target proteins to characterise their structural and functional properties, providing the foundation for precise AI-guided predictions and optimisations.
3
Algorithm Selection
Select the most appropriate machine learning and AI algorithms — from geometric deep learning to transformer-based architectures — based on the specific demands of each antibody design project.
4
Sequence Generation
Generate and iteratively refine antibody sequences using advanced generative AI techniques, ensuring each candidate meets target binding specifications and exhibits optimal in silico performance.
Advantages of Our Antibody Drug Design Service
Advanced Deep Learning Algorithms
Deliver precise improvements in binding affinity and target specificity through state-of-the-art sequence modelling.
High-Throughput Screening
Rapidly identify the highest-confidence candidates from millions of computationally evaluated variants.
Robust Wet Lab Validation
Guarantee functional stability and real-world effectiveness through integrated experimental confirmation at every stage.
Partnering with ICDMO for your antibody drug development programme delivers reduced costs, accelerated timelines, and meaningfully improved success rates. Contact our team today to advance your research and development initiatives with our comprehensive, AI-first solutions.
* For research use only. Not intended for any clinical use.
Quick Inquiry
Fill in the form below and our team will respond with a detailed proposal within one business day.